Free Access
Volume 54, Number 1, January-March 2019
Page(s) 55 - 59
Published online 28 February 2019
  • Bernard D et al. 2014. Radioiodine therapy in benign thyroid disorders. Evaluation of French nuclear medicine practices. Ann. d’Endocrinol. 75: 241–246. [CrossRef] [Google Scholar]
  • Bessières I, Vrigneaudab JM, Toubeaub M, Cochetb A, Dygaï-Cochetb I. 2017. Radioprotection de l’entourage des patients traités à l’iode 131 pour des cancers différenciés de la thyroïde : comparaison de deux méthodes d’estimation des temps de restriction de contact. Méd. Nucl. 41: 397–40. [Google Scholar]
  • Commission Européenne. 1999. Radioprotection 97. Radioprotection à la suite d’une thérapie à l’iode 131. Disponible sur [Google Scholar]
  • Cooper DS et al. 2006. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16: 109–142. [CrossRef] [PubMed] [Google Scholar]
  • ICRP Publication 103. 2007. Recommandations de la Commission Internationale de la Protection Radiologique. Disponible sur [Google Scholar]
  • Leslie WD, Havelock J, Palser R, Abrams DN. 2002. Large-body radiation doses following radioiodine therapy. Nucl. Med. Commun. 23: 1091–7. [CrossRef] [PubMed] [Google Scholar]
  • Markou P, Chatzopoulos D. 2004. Isolation period prediction in patients with differentiated thyroid carcinoma treated after thyroidectomy by radioiodine-131. Hell J. Nucl. Med. 7: 195–8. [Google Scholar]
  • Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. 2006. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154: 787–803. [Google Scholar]
  • Remy H et al. 2008. 131I effective half-life and dosimetry in thyroid cancer patients. J. Nucl. Med. 49: 1445–50. [CrossRef] [PubMed] [Google Scholar]
  • Remy H et al. 2012. Thyroid cancer patients treated with 131I: radiation dose to relatives after discharge from the hospital. Thyroid 22: 59–63. [CrossRef] [PubMed] [Google Scholar]
  • Van Dyke M, Punja M, Hall MJ, Kazzi Z. 2015. Evaluation of toxicological hazards from medical radioiodine administration. J. Med. Toxicol. 11: 96–101. [Google Scholar]
  • Zhang R, Zhang G, Wang R, Tan J, He Y, Meng Z. 2017. Prediction of thyroidal 131I effective half-life in patients with Graves’ disease. Oncotarget 8: 80934–80940. [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.